Harpreet Singh, Immatics CEO

Im­mat­ics un­veils promis­ing, ear­ly-stage da­ta for a top con­tender in the race to de­vel­op TCRs. Now it has to live up to ex­pec­ta­tions

Im­mat­ics has scored a sig­nif­i­cant ad­vance in its quest to de­vel­op cell ther­a­pies for sol­id tu­mors.

Tues­day morn­ing the biotech — based in Ger­many with a big op­er­a­tion in Hous­ton — took the wraps off a set of promis­ing pre­lim­i­nary da­ta from an ear­ly-stage study of its TCR ther­a­py, IMA203.

Ex­am­in­ing the drug’s ef­fect on 16 can­cer pa­tients who had al­ready en­dured a me­di­an of 4 pre­vi­ous sys­temic treat­ments, re­searchers con­clud­ed that half — 8 — of them had reg­is­tered an ob­jec­tive re­sponse against a range of sol­id tu­mor types. Three of the pa­tients who didn’t re­spond were on the very low­est dose, the least like­ly to re­spond, while in­ves­ti­ga­tors tracked en­cour­ag­ing dose re­spons­es at high­er lev­els.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.